Belgian start-up closes first round with €20M

The Belgian spin-off of VIB, ActoGeniX, has garnered a total of €20 million in its first round. GIMV is adding €8 million in a second tranche, with Life Sciences Partners acting as co-lead investor. New investors include Aescap, Ventech and Baekeland Fonds. ActoGeniX is developing a pipeline of therapeutic products based on its TopActTM technology platform, a proprietary delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals. VIB and Ghent University, the original inventors of this technology, transferred the IP to ActoGeniX.

- see the release on the venture round

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.